Yüklüyor......
Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths. Patients with advanced HCC are treated with sorafenib. A recent randomized controlled trial demonstrated a survival benefit for regorafenib treatment in patients with advanced HCC who had progr...
Kaydedildi:
| Yayımlandı: | PLoS One |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Public Library of Science
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6224101/ https://ncbi.nlm.nih.gov/pubmed/30408106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0207132 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|